GU Cancers 2024 | Management of urothelial cancer with combination immunotherapies

Monika Joshi, MD, Penn State Cancer Institute, Hershey, PA, comments on the utility of combination immunotherapy strategies to treat urothelial cancer. Radiotherapy and immunotherapy have been found to have a synergistic effect, where radiotherapy can sensitize tumors to immune checkpoint inhibitors. Trials such as Phase III S1806 (NCT03775265) and EA8192 (NCT04628767) trials assessing chemotherapy with atezolizumab and durvalumab respectively are also underway. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.